
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
In an interview with Pharmacy Times, Brian Wortz, PharmD, said he enjoys the innovation in his research, especially when their findings have the potential to drastically impact patients’ lives.
In his work with Cancer Treatment Centers of America, research pharmacist Brian Wortz, PharmD, specializes in oncology clinical research. In an interview with Pharmacy Times, Wortz said he enjoys the innovation in his research, especially when their findings have the potential to drastically impact patients’ lives.





